LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Lisa K. Miller Sells 18,845 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Lisa K. Miller sold 18,845 shares of LifeStance Health Group stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the sale, the insider now directly owns 339,810 shares of the company’s stock, valued at approximately $2,344,689. This trade represents a 5.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

LifeStance Health Group Price Performance

Shares of LFST opened at $6.81 on Thursday. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $8.61. The stock has a market cap of $2.62 billion, a PE ratio of -26.19 and a beta of 1.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. The firm has a fifty day moving average price of $7.75 and a 200 day moving average price of $7.35.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in shares of LifeStance Health Group by 124.4% in the fourth quarter. Blue Trust Inc. now owns 3,828 shares of the company’s stock valued at $27,000 after buying an additional 2,122 shares during the last quarter. Townsquare Capital LLC acquired a new position in shares of LifeStance Health Group during the third quarter worth about $73,000. R Squared Ltd acquired a new position in shares of LifeStance Health Group during the fourth quarter worth about $80,000. Ameriprise Financial Inc. acquired a new position in shares of LifeStance Health Group during the fourth quarter worth about $87,000. Finally, Cibc World Markets Corp acquired a new position in shares of LifeStance Health Group during the fourth quarter worth about $96,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group raised shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Monday, December 16th. William Blair reaffirmed an “outperform” rating on shares of LifeStance Health Group in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.63.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.